Melbourne Urologist
Dr Pras Sivam FRACS (Urol)

Dr Pras Sivam FRACS (Urol)

Urologist, Uro-Oncologist and Robotic Surgeon

Dr Pras Sivam (Prassannah Satasivam) is a Fellow of the Royal Australasian College of Surgeons and Member of the Society of Urologic Oncology.

Pras grew up in Melbourne and graduated from Haileybury College as Dux of the School in 1998. He joined the University of Melbourne Medical School with a tertiary entrance rank of 99.95. After completing his postgraduate surgical training in Victoria, he accepted a prestigious Fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York. This gave him formal training under global leaders in the field of urology.  Click here to learn more …

In the news …

Dr Pras was recently awarded the 2022 Alban Gee Award at the Annual Meeting of the Urological Society of Australian and New Zealand, this year held at the Gold Coast Convention Centre. This award has been presented since 1987 for the best poster by a USANZ member at the Annual Scientific Meeting.

Dr Pras’s poster, titled “Factors impacting clinician reluctance to defer prostate biopsy in men with a negative multiparametric MRI,” highlighted the reluctance of clinicians to defer prostate biopsy in men with negative MRI findings.


Melbourne Urologist Robotic Prostatectomy Prostate Cancer

Please click below for detailed descriptions of common operations, including robotic prostatectomy, prostate biopsy, stone surgery, TURP and surgery for kidney, bladder and testis cancer. 

A unique approach

Dr Pras Sivam’s unique approach to robotic prostatectomy combines elements of both the traditional “anterior” and newer “posterior” techniques.  This allows his patients recover continence earlier whilst maintaining excellent cancer control.

Early continence recovery

In a recent audit, we found that 39% of our patients achieved continence (0 pads or 1 security pad) within 2 weeks of surgery, and 65 % within 2 months. Few studies have looked at continence this early after surgery, however one large systematic review reported 3-month continence rates ranging from 25% to 90% (1).

Excellent cancer control

In a recent audit, we achieved superior cancer control rates with a positive margin rate of 0% for organ-confined cancer (stage pT2) and 17% for locally-advanced cancer (stage pT3). For comparison, in one large systematic review the average positive margin rate was 9% for pT2 (range: 4–23%) and 37% for pT3 cancers (range: 29–50%) (2).

(1) Ficarra et al. European Urology, Volume 62 Issue 3, September 2012, Pages 405-417.

(2) Novara et al. European Urology, Volume 62 Issue 3, September 2012, Pages 382-404.

robotic prostatectomy

Prostate Cancer

Should you have a PSA test? How do we diagnose and treat prostate cancer? How do we manage the side-effects of treatment?

Robotic prostatectomy

Bladder Cancer

What causes bladder cancer? When must we remove the entire bladder with surgery?

Robotic prostatectomy

Kidney Cancer

What is the role of biopsy in kidney cancer? Do all kidney tumours need surgery? When can we watch a kidney tumour?

Robotic prostatectomy

Testis Cancer

What are the symptoms of testis cancer? How is it treated and can it be cured?

Benign Enlarged Prostate

What are the symptoms of having an enlarged prostate? What treatment options are available?

Melbourne Urologist

Kidney Stones

What causes kidney stones and what can I do to prevent them? How do we treat kidney stones?